1252554-86-1

Basic information

• Product Name: 4-bromo-2,6-difluoro-N-{2-hydroxy-5-[(methylamino)sulfonyl]phenyl}benzamide
• Synonyms: 4-bromo-2,6-difluoro-N-{2-hydroxy-5-[(methylamino)sulfonyl]phenyl}benzamide
• CAS NO: 1252554-86-1
• Molecular Weight: 421.219
• Mol File: 1252554-86-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-bromo-2,6-difluoro-N-{2-hydroxy-5-[(methylamino)sulfonyl]phenyl}benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-2,6-difluoro-N-{2-hydroxy-5-[(methylamino)sulfonyl]phenyl}benzamide(1252554-86-1)
• EPA Substance Registry System: 4-bromo-2,6-difluoro-N-{2-hydroxy-5-[(methylamino)sulfonyl]phenyl}benzamide(1252554-86-1)

Safety Data

• Hazardous Substances Data: 1252554-86-1(Hazardous Substances Data)

Upstream product

• 497181-19-8 2,6-difluoro-4-bromobenzoyl chloride 
• 80-23-9 3-amino-4-hydroxy-N-methylbenzenesulfonamide 

Relevant articles and documents

CHEMICAL COMPOUNDS

The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.